title: Alvimopan (Adolor/GlaxoSmithKline).
abstract: Alvimopan is a potent, peripherally active, mu-opioid receptor antagonist being developed by Adolor and GlaxoSmithKline (GSK) as a potential treatment for post-operative ileus and opioid bowel dysfunction.
authors.affiliation: University of Chicago, Department of Medicine, IL 60637, USA.
authors.forename: Ijeoma A
authors.initials: IA
authors.lastname: Azodo
authors.forename: Eli D
authors.initials: ED
authors.lastname: Ehrenpreis
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D006801:Humans; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D010880:Piperidines / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D017450:Receptors, Opioid, mu / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship
chemical_list: D009292:Narcotic Antagonists; D010880:Piperidines; D017450:Receptors, Opioid, mu; C419502:alvimopan